Speakers:
- Kenneth (Ken) Bradley, Global Head, Infectious Disease Discovery, Roche (Switzerland)
- Diarmaid Hughes, Professor of Medical Molecular Bacteriology, Uppsala University (Sweden)
Moderator:
- Karen Bush, Professor of Practice in Biotechnology, Emerita, Indiana University (USA)
Presentation 1: Progression criteria and Go/NoGo decisions in antibacterial drug discovery – an industry view (Ken Bradley)
- Drug discovery starts and ends with the patient.
- Target product profiles (TPPs) guide R&D.
- Target candidate profiles (TCPs) provide guidance and enable Go/NoGo decision making for preclinical programs.
- Examples will be provided to showcase decision making in preclinical research.
Presentation 2: Progression criteria and Go/NoGo decisions in antibacterial drug discovery – an academic view (Diarmaid Hughes)
- The academic research environment as it relates to antibiotic discovery.
- Serendipity versus planning in academic antibiotic discovery.
- The importance of projects like ENABLE in guiding academic researchers along the path to a useful drug.
This live webinar including an interactive Q&A session was broadcast on 9 April 2024.
If you have questions or comments, please let us know: revive@gardp.org.